Highlights Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
1.28 ^USD	-1.54%		-5.19%	-19.50%

05-30	Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	CI
05-24	Cyclo Therapeutics Files $100 Million Mixed Shelf	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	05-30	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	03-14	MT
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	12-27	MT
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	12-26	CI
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	12-18	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge	21/09/23	MT
Cyclo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Cyclo Therapeutics Says European Patent Office Grants Allowance of Trappsol Cyclo Patent; Shares Rise	12/06/23	MT
Cyclo Therapeutics Signs $5 Million Funding Deal with Rafael Holdings	05/06/23	MT
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Cyclo Therapeutics Says in Preliminary Talks with Potential Strategic Parties	20/03/23	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/03/23	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/03/23	CI
Cyclo Therapeutics, Inc. Provides Clinical Program Update	11/01/23	CI
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease	09/01/23	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1	18/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Highlights

Filters